Forward P/S Multiple: Anika Therapeutics Inc. (ANIK)

Anika Therapeutics, Inc. - graphic logo of issuer ANIK

Anika Therapeutics automates the sterilization and dosing of regenerative medicine drugs, minimizing manual labor. The expected price-to-sales ratio visualizes market expectations for the issuer, while 1.40 captures the current value of the indicator. Proprietary hyaluronic acid-based methods simplify joint rehabilitation, and strict FDA regulations and patent protection create a sustainable barrier for new entrants.

Anika Therapeutics, Inc. - ANIK Market Cap to Projected Revenue (period 07/04/2022 - 11/17/2026)

Summary analytical data breakdowns for Anika Therapeutics, Inc. (ANIK)

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Fundamental company analysis:ANIK (anikatherapeutics.com)
Product sample of anikatherapeutics.com

This indicator compares the current market value of Anika Therapeutics (ANIK) with expected annual sales volume, allowing for a real-time assessment of the cost of each unit of future revenue. The forward P/S trend reflects market expectations regarding the implementation of high-precision robotic sterilization and dosing systems, where production automation directly impacts business scalability and the company's investment attractiveness.

Who Anika Therapeutics competes with

Forward P/S Multiple BSX (bostonscientific.com)|EW: Market Cap to Projected Revenue|ResMed - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Corporation|ZBH: Forward P/S Multiple|COO - Market Cap to Expected Sales Ratio|ALGN (Align Corp) - Forward P/S Multiple|Globus Medical Corp (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TMDX|Forward Price-to-Revenue Multiple Alphatec Holdings, Inc. ATEC|Forward P/S Multiple AORT (artivion.com)|Forward P/S Multiple Enovis Corp ENOV|IART - Price-to-Projected Revenue Ratio|ESTA: Price-to-Projected Revenue Ratio|BBNX (Beta Bionics Inc) - Forward Price-to-Revenue Multiple|IRADIMED CORPORATION - Forward Price to Sales|EMBC (Embecta Health) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Tandem Diabetes Care Inc TNDM|Price-to-Projected Revenue Ratio AxoGen Inc (AXGN)|SI-BONE, Inc. (SIBN) - Projected Price to Revenue|Orthofix Corp - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio bioventus.com (BVS)|OrthoPediatrics Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio Treace Medical Concepts Inc TMCI|Strata Critical Medical (SRTA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CARL (Carlsmed Medical)|Price-to-Projected Revenue Ratio rxsight.com|Forward Price-to-Revenue Multiple ClearPoint Neuro, Inc. (CLPT)|Forward P/S Multiple STXS|STIM - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Sight Sciences, Inc. SGHT|OBIO: Market Cap to Projected Revenue|NSPR: Forward Price-to-Revenue Multiple|Jin Medical - Price to Expected Revenue Ratio|VANI (Vivani Medical Inc) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue XTNT|NMTC (n1mtc.com) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Modular Medical MODD|Price-to-Projected Revenue Ratio myomo.com (MYO)|Price-to-Projected Revenue Ratio COCH (envoymedical.com)|Price-to-Projected Revenue Ratio Vivos Therapeutics Inc VVOS|enVVeno Medical Corp. - Price-to-Projected Revenue Ratio|SINT: Forward Price-to-Revenue Multiple|TNON (Tenon Medical, Inc.) - Market Cap to Projected Revenue|Lifeward Ltd. (LFWD) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Autonomix (AMIX)|Price-to-Projected Revenue Ratio INVO Fertility|Bone Biologics Corp. (BBLG) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple AXNX (Axonics Modulation Technologies)|BIOL (Biolase, Inc.) - Forward Price to Sales|Forward P/S Multiple DYNT (dynatronics.com)|Forward Price to Sales FNA|INVO Bioscience - Forward P/S Multiple